Praxis reports RADIANT study positive: 56.3% median seizure reduction; Q2 net loss $71.1M

Praxis Precision Medicines, Inc.

Vormatrigine in focal onset seizures (n=37): 56.3% median reduction in seizure frequency over 8 weeks; 22% achieved 100% reduction in last 28 days.
Cash and investments $446.6M at June 30, 2025, providing runway into 2028.
Q2 2025 net loss $71.1M vs $32.7M in Q2 2024; R&D expenses rose to $63.0M from $27.3M.
Relutrigine received FDA Breakthrough Therapy Designation for SCN2A and SCN8A DEEs in July 2025.
Initiated registrational studies: EMERALD (broad DEEs with relutrigine) and EMBRAVE3 (SCN2A GoF with elsunersen).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.